These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21142545)

  • 21. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.
    Bristow RE; Chi DS
    Gynecol Oncol; 2006 Dec; 103(3):1070-6. PubMed ID: 16875720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neoadjuvant chemotherapy for advanced epithelial ovarian cancer].
    Hatae M; Onishi Y; Nakamura T; Yamamoto H; Kusumoto M; Matsui T; Mihara K; Taniguchi H
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1833-7. PubMed ID: 11729475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Pelvic and Para-aortic Lymphadenectomy in Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.
    Schwartz L; Schrot-Sanyan S; Brigand C; Baldauf JJ; Wattiez A; Akladios C
    Anticancer Res; 2015 Oct; 35(10):5503-9. PubMed ID: 26408716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The optimal time for surgery in women with serous ovarian cancer.
    Stewart JM; Tone AA; Jiang H; Bernardini MQ; Ferguson S; Laframboise S; Murphy KJ; Rosen B; May T
    Can J Surg; 2016 Aug; 59(4):223-32. PubMed ID: 27240134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer.
    Weinberg LE; Rodriguez G; Hurteau JA
    J Surg Oncol; 2010 Mar; 101(4):334-43. PubMed ID: 20187069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment.
    Onda T; Yoshikawa H; Yasugi T; Matsumoto K; Taketani Y
    Jpn J Clin Oncol; 2010 Jan; 40(1):36-41. PubMed ID: 19820253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
    Tropé CG; Elstrand MB; Sandstad B; Davidson B; Oksefjell H
    Eur J Cancer; 2012 Sep; 48(14):2146-54. PubMed ID: 22382201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgery for recurrent ovarian cancer.
    Heitz F; du Bois A; Kurzeder C; Pfisterer J; Barinoff J; Grabowski J; Hilpert F; Mahner S; Harter P
    Womens Health (Lond); 2011 Sep; 7(5):529-35. PubMed ID: 21879821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aggressive surgery and ovarian cancer.
    Chi DS; Barakat RR
    J Clin Oncol; 2006 May; 24(15):2395-6; author reply 2396-7. PubMed ID: 16710043
    [No Abstract]   [Full Text] [Related]  

  • 31. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?
    Eisenkop SM; Spirtos NM
    Gynecol Oncol; 2001 Sep; 82(3):489-97. PubMed ID: 11520145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Up-date on cytoreductive surgery in the management of advanced ovarian cancer].
    Angioli R; Palaia I; Damiani P; Montera R; Benedetti Panici P
    Minerva Ginecol; 2006 Dec; 58(6):459-70. PubMed ID: 17108876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The role of interval surgery in the treatment's strategy of advanced ovarian cancer].
    Jaffré I; Bordes V; Dejode M; Dravet F; Frénel JS; Berton-Rigaud D; Classe JM
    Bull Cancer; 2011 Jan; 98(1):37-42. PubMed ID: 21282089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer.
    Lim MC; Song YJ; Seo SS; Yoo CW; Kang S; Park SY
    Onkologie; 2010; 33(6):324-30. PubMed ID: 20523098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A statement for extensive primary cytoreductive surgery in advanced ovarian cancer.
    Pomel C; Barton DP; McNeish I; Shepherd J
    BJOG; 2008 Jun; 115(7):808-10. PubMed ID: 18485155
    [No Abstract]   [Full Text] [Related]  

  • 36. [Advanced ovarian cancer: primary debulking (PDS) or neoadjuvant chemotherapy (NACT) - still a debate].
    Segev Y; Gemer O; Auslender R; Lavie O
    Harefuah; 2014 Sep; 153(9):527-31, 558. PubMed ID: 25417489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second-look operation improves survival in suboptimal, debulked, stage III ovarian cancer.
    Escobar PF; Michener CM; Rose PG
    Int J Gynecol Cancer; 2005; 15(6):1258; author reply 1259. PubMed ID: 16343227
    [No Abstract]   [Full Text] [Related]  

  • 38. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
    Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
    Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial.
    van Meurs HS; Tajik P; Hof MH; Vergote I; Kenter GG; Mol BW; Buist MR; Bossuyt PM
    Eur J Cancer; 2013 Oct; 49(15):3191-201. PubMed ID: 23850170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Neoadjuvant chemotherapy in the treatment of ovarian cancer].
    Lehoczky O
    Orv Hetil; 2005 Sep; 146(38):1951-5. PubMed ID: 16238247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.